Key Insights

• C4 Therapeutics will host its Annual General Meeting on 20th of June

• Salary of US$639.0k is part of CEO Andrew Hirsch's total remuneration

• Total compensation is similar to the industry average

• C4 Therapeutics' three-year loss to shareholders was 87% while its EPS was down 2.9% over the past three years

Shareholders will probably not be too impressed with the underwhelming results at C4 Therapeutics, Inc. (NASDAQ:CCCC) recently. At the upcoming AGM on 20th of June, shareholders can hear from the board including their plans for turning around performance. This will be also be a chance where they can challenge the board on company direction and vote on resolutions such as executive remuneration. We present the case why we think CEO compensation is out of sync with company performance.

View our latest analysis for C4 Therapeutics

Comparing C4 Therapeutics, Inc.'s CEO Compensation With The Industry

According to our data, C4 Therapeutics, Inc. has a market capitalization of US$331m, and paid its CEO total annual compensation worth US$3.8m over the year to December 2023. We note that's an increase of 46% above last year. While we always look at total compensation first, our analysis shows that the salary component is less, at US$639k.

For comparison, other companies in the American Biotechs industry with market capitalizations ranging between US$200m and US$800m had a median total CEO compensation of US$3.2m. From this we gather that Andrew Hirsch is paid around the median for CEOs in the industry. Furthermore, Andrew Hirsch directly owns US$1.0m worth of shares in the company.

Speaking on an industry level, nearly 23% of total compensation represents salary, while the remainder of 77% is other remuneration. In C4 Therapeutics' case, non-salary compensation represents a greater slice of total remuneration, in comparison to the broader industry. It's important to note that a slant towards non-salary compensation suggests that total pay is tied to the company's performance.

C4 Therapeutics, Inc.'s Growth

C4 Therapeutics, Inc. has reduced its earnings per share by 2.9% a year over the last three years. It saw its revenue drop 26% over the last year.

The lack of EPS growth is certainly uninspiring. And the fact that revenue is down year on year arguably paints an ugly picture. So given this relatively weak performance, shareholders would probably not want to see high compensation for the CEO. Looking ahead, you might want to check this free visual report on analyst forecasts for the company's future earnings..